ABSTRACT: The Seattle Biotech community encompasses over 100 companies and has cultivated some of the biggest drugs on the market today. Enbrel, Cialis, and Provenge were all developed in our backyard. In recent days there has been an explosion of new companies built on cutting edge science and technologies aimed at developing the next pillars of medicine. In many of these companies you will find Chemical Engineers making incredible contributions across a diverse collection of functions. Research, Development, Manufacturing, Legal, Quality; name a function and odds are you can find a Chemical Engineer serving in that role. In this seminar, I will share a few examples of how Chemical Engineers find their way into the Seattle Biotech community, provide information on a few of the exciting technologies and companies poised to need the services of Chemical Engineers in the coming days, and hopefully convince you to consider Seattle Biotech as a potential career pathway.

BIOGRAPHY: Brian earned his B.S. in Chemical Engineering from the University of Washington in 2010. Brian Christin currently serves as the CMC Lifecycle Management Lead for Domestic Operations at Juno Therapeutics. He began his career in the Solar Power industry where he served a short stint as a Process Development Engineer within a Solar Panel Startup that ultimately closed its doors due to lack of funding. Looking for a new direction, he happened upon the Seattle Biotech community where he found a dynamic and passionate environment that has provided opportunities not previously considered when exiting the University of Washington. Brian began his career in Seattle Biotech at the Dendreon Corporation, serving in Process Development, Process Engineering, and Quality Engineering functions aimed at commercializing Provenge, the first FDA-approved therapeutic cancer vaccine. He was then one of the first employees of Juno Therapeutics, where he has worked in many facets including Technology Transfer, Process Development, Process Engineering, and Process Characterization in an effort to bring CAR-T cell therapies to patients in dire need of more effective treatments.